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Abstract   
Background: Vasospastic angina (VSA), which often causes acute coronary syndrome 
(ACS), can be diagnosed by intracoronary acetylcholine (ACh) provocation test. 
However, the safety and usefulness of ACh provocation test in ACS patients on 
emergency coronary angiography (CAG) compared to non-emergency settings is unclear.  
Methods: A total of 529 patients undergoing ACh provocation test during emergency or 
non-emergency CAG were included. Patients with resuscitated cardiac arrest were 
excluded. The primary endpoint was adverse events defined as a composite of death, 
ventricular fibrillation or sustained ventricular tachycardia, myocardial infarction, 
cardiogenic shock, cardiac tamponade, and stroke within 24 hours after ACh provocation 
test.  
Results: There were no significant differences of the clinical characteristics between the 
groups of emergency (n=84) and non-emergency (n=445) ACh provocation test. The rate 
of positive ACh provocation test was similar between the 2 groups (50% vs. 49%, p=0.81). 
Similarly, the incidence of adverse events in patients with emergency and non-emergency 
ACh provocation test did not significantly differ (1.2% vs. 1.3%, p=1.00). 
Conclusion: ACh provocation test can be safely performed in ACS patients with no 
obstructive culprit lesions on emergency CAG, and may be useful to diagnose VSA in 
those patients. 
  
1. Introduction 
Vasospastic angina (VSA) is an important disorder which can cause acute coronary 
syndrome (ACS) and sudden cardiac death [1]. Recent guidelines across the world 
recommend intracoronary provocative test with acetylcholine (ACh) or ergonovine (ER) 
in suspected VSA patients (class I, IIa, or IIb) [2-4]. It is well-known that 8% to 12% of 
patients with ACS are found to have absent or only angiographically mild coronary 
lesions [5,6]. This phenomenon is recognized as myocardial infarction (MI) with non-
obstructive coronary arteries (MINOCA), in which VSA is a common etiology [5]. 
Although a recent study indicated the feasibility of intracoronary provocative test on 
emergency coronary angiography (CAG) [5,7], the safety of intracoronary provocative 
test for ACS patients on emergency CAG have not been fully understood, especially 
compared to those with non-emergency settings. The aim of this study was to evaluate 
the safety and usefulness of ACh provocation test in ACS patients with no culprit lesions 
on emergency CAG compared to those with the elective tests. 
  
2. Methods 
2.1. Study Population 
From June 2012 to June 2017, a total of 546 patients underwent intracoronary ACh 
provocation test at Chiba University Hospital. Patients with resuscitated cardiac arrest 
(n=17) were excluded. Thus, 529 patients were included in the present study and divided 
into 2 groups: emergency and non-emergency ACh provocation test. Emergency ACh test 
was defined as the intracoronary provocative test during the same angiographic session 
of emergency CAG performed within 24 hours after hospital admission due to ACS. 
Written informed consent for examination was obtained from all patients, and the ethical 
committee of Chiba University approved this study.  
2.2 Intracoronary Acetylcholine Provocation Test 
 Intracoronary ACh provocation tests were performed according to the 
guidelines for diagnosis and treatment of patients with VSA by Japanese Circulation 
Society [2], as previous reported [8]. In brief, all vasodilators were discontinued at least 
48 hours before the examination in non-emergency ACh test. After insertion of a 
temporary pacing electrode in the right ventricle via basilic, cephalic or internal jugular 
vein, ACh was injected in incremental doses of 20, 50 and 100 µg into the left coronary 
artery (LCA), and 20 and 50 µg into the right coronary artery (RCA) over a period of 20 
seconds. In Chiba University Hospital, ACh provocation test was performed the same 
angiographic session of emergency CAG when there were no obstructive culprit lesions 
in ACS cases without other causes than suspected coronary vasomotor abnormalities such 
as myocarditis, Takotsubo cardiomyopathy, and severe renal dysfunction. 
2.3. Definitions 
 Angiographic coronary artery spasm was defined as total or subtotal occlusion 
induced by ACh provocation test. It was evaluated by 2 experienced cardiologists who 
were blinded to patients’ clinical characteristics. The positive diagnosis of intracoronary 
ACh provocation test was defined as angiographic coronary artery spasm accompanied 
by chest pain and/or ischemic electrocardiographic changes. Multivessel spasm was 
defined as ACh-induced coronary artery spasm of ≥2 major epicardial arteries. 
 ACS was defined as unstable angina or acute MI. The diagnosis of acute MI 
was based on the third universal definition of myocardial infarction [9]. The diagnosis of 
MINOCA was made based on the following criteria: 1) universal acute MI criteria, 2) 
non-obstructive coronary arteries on CAG, defined as no coronary stenosis ≥ 50%, 3) no 
clinically overt specific causes for the acute presentation [10]. Unstable angina was 
diagnosed using Braunwald’s criteria [11].  
 The primary endpoint of the present study was major adverse events defined as 
a composite of death, ventricular fibrillation (VF) or sustained ventricular tachycardia 
(VT) requiring electrical cardioversion, MI, cardiogenic shock, cardiac tamponade, and 
stroke within 24 hours after ACh provocation test. Non-sustained VT and paroxysmal 
atrial fibrillation (AF) during the procedures were also recorded.  
2.4. Statistical Analysis 
 Statistical analysis was performed with SAS statistical software package 
version 9.4 (SAS Institute, Cary, NC, USA). Continuous variables are expressed as mean 
± standard deviation when normally distributed, and as median and interquartile range 
when non-normally distributed. Categorical data are presented as absolute numbers and 
percentages. Continuous variables were compared using unpaired Student’s t-test or 
Mann-Whitney U-test, as appropriate. Categorical variables were compared with chi-
square test or Fisher’s exact test. A value of p <0.05 was considered statistically 
significant. 
 
3. Results 
Clinical characteristics of the study population and ACh provocation test are shown in 
Table 1. There were no significant differences between the groups of emergency and non-
emergency ACh provocation test. Although patients with emergency ACh test developed 
either MINOCA or unstable angina (Table 1), the characteristics in subjects with 
MINOCA did not significantly differ compared to those with unstable angina except for 
a history of AF (25% vs. 7%, p=0.04). Additionally, in the emergency group, 5 out of 28 
patients (18%) with MINOCA had ST-segment elevation on arrival. Table 2 shows 
adverse events in patients with emergency and non-emergency ACh provocation test. The 
rate of major cardiovascular complications did not significantly differ between the 2 
groups. There was 1 case of VF induced by ACh injection into the RCA, which was 
immediately terminated by electrical cardioversion, and 1 case of acute MI possibly due 
to prolonged coronary spasm in the distal RCA, in patients with non-emergency ACh test. 
Cardiogenic shock induced by severe vasospasm occurred in 3 patients. In addition, there 
were 2 cases of ischemic stroke presented partial visual field impairment and mild 
dysarthria in patients with non-emergency ACh provocation test. Both cases of stroke 
were confirmed by magnetic resonance imaging. The incidence of non-sustained VT and 
paroxysmal AF was also similar between the 2 groups (Table 2). 
  
4. Discussion 
The main findings of the present study is that in patients undergoing ACh provocation 
test during the same angiographic session of emergency CAG, the rate of adverse events 
was low and comparable to those on non-emergency settings. 
4.1. Safety of Emergency Acetylcholine Test 
Previous studies have reported low rates of complications with ACh provocation test [12-
14]. However, the safety of ACh provocation tests have been established mostly based on 
those with elective status. Ong et al. showed coronary spasm could be documented by 
ACh test in nearly half of the patients with suspected ACS and no culprit lesions [15]. 
ACh provocation test in that study was performed either at primary catheterization or in 
a second session, and the complications were not reported. Montone et al. recently 
demonstrate that intracoronary provocative test with ACh or ER was safe and can identify 
a high-risk subset of patients presenting with MINOCA [5]. In this study, intracoronary 
ACh test was performed in 43 patients without any complication. Although there were 
some previous reports which suggested the usefulness of ACh provocation test in ACS 
patients without culprit lesions [16,17], no studies have directly compared ACh test in the 
emergency (i.e. ACS) versus non-emergency settings. In the present study, we focused on 
the safety of intracoronary ACh provocation test during emergency CAG performed 
within 24 hours after hospital admission due to ACS, compared to those with the elective 
tests. ACh provocation test is not recommended during emergency CAG performed in 
patients with ACS in the Japanese Circulation Society guidelines [2]. Similarly, the 
American Heart Association and American College of Cardiology guidelines also 
indicated that intracoronary provocative test may be undertaken after a period of 
stabilization [4]. In addition, although a recent position paper recommends provocative 
testing for the MINOCA patients, it is also mentioned that the procedure should generally 
be avoided in the acute phase of MI [18]. However, the present study suggested that ACh 
provocation test during the same angiographic session of emergency CAG can be safely 
performed as on non-emergency CAG.  
Interestingly, the incidence of positive ACh provocation test in the emergency 
group was comparable to those in the non-emergency group, although 35% of patients in 
the emergency group were under continuation of vasodilators. The findings may allow to 
avoid the second CAG with provocative test, possibly leading to the reduced medical cost 
and catheterization complications. Additionally, in patients with MINOCA, AF was more 
prevalent compared to those with unstable angina who had no culprit lesions (25% vs. 
7%). Tachycardia including AF can account for MINOCA [4], thus there is a possibility 
that some patients with negative emergency ACh test developed MINOCA actually due 
to AF. 
4.2. Study Limitations 
There are some limitations in the present study. First, this is the single center 
retrospective study. Since the adverse events were not frequent, the sample size was 
relatively small. Second, although the incidence of AF was higher in patients with 
MINOCA compared to those with unstable angina, the finding is probably due to selection 
bias. Third, patients with resuscitated cardiac arrest were excluded in the present study. 
VSA was reported as an important cause of cardiac arrest, with the prevalence ranging 
from 3% to 11% of patients with out-of-hospital cardiac arrest survivors [19,20]. 
 
5. Conclusion 
ACh provocation test can be safely performed in ACS patients with no obstructive culprit 
lesions on emergency CAG, and may be useful to diagnose VSA in those patients.  
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 Table 1. Patient and ACh Provocation Test Characteristics 
Variable All 
(n=529) 
Emergency 
(n=84) 
Non-Emergency 
(n=445) 
P value 
Age (years) 64.1±12.5 64.8±13.4 64.0±12.6 0.30 
Male 275 (52%) 43 (51%) 232 (52%) 0.87 
Hypertension 329 (62%) 59 (70%) 270 (61%) 0.10 
Diabetes mellitus 96 (18%) 16 (19%) 80 (18%) 0.82 
Dyslipidemia 349 (66%) 53 (63%) 296 (67%) 0.54 
Current smoker 96 (18%) 14 (17%) 82 (18%) 0.70 
Prior myocardial infarction 47 (9%) 7 (8%) 40 (9%) 0.85 
eGFR (ml/min/1.73 m2) 76.0±19.5 76.9±22.3 75.9±19.3 0.33 
History of AF 41 (8%) 11 (13%) 30 (7%) 0.24 
Clinical presentation     
 MINOCA 28 (5%) 28 (33%) - - 
 Unstable angina 56 (11%) 56 (67%) - - 
 Rest angina 325 (61%) - 325 (73%) - 
 Effort angina 11 (2%) - 11 (2%) - 
Rest and effort angina 91 (17%) - 91 (20%) - 
 Other 18 (3%) - 18 (4%) - 
Medical treatment     
Calcium channel blocker 244 (46%) 23 (27%) 221 (50%) <0.001 
Long-acting nitrate 95 (18%) 10 (11%) 85 (19%) 0.12 
Nicorandil 42 (8%) 4 (5%) 38 (9%) 0.38 
b blocker 80 (15%) 17 (20%) 63 (14%) 0.15 
ACE-I or ARB 178 (34%) 33 (39%) 145 (33%) 0.23 
Antiplatelet 165 (31%) 23 (27%) 142 (32%) 0.41 
Anticoagulant 31 (6%) 10 (11%) 21 (5%) 0.01 
Statin 199 (38%) 27 (32%) 172 (39%) 0.26 
Coronary artery with provoked spasm     
Right 155 (29%) 21 (25%) 134 (30%) 0.35 
Left anterior descending 249 (47%) 43 (51%) 206 (46%) 0.41 
Left circumflex 94 (18%) 18 (21%) 76 (17%) 0.34 
Multivessel spasm 150 (28%) 21 (25%) 129 (29%) 0.46 
Signs of ischemia     
 Electrocardiographic change 204 (39%) 38 (45%) 166 (37%) 0.17 
Chest pain 292 (52%) 48 (57%) 244 (55%) 0.70 
Positive ACh provocation test 258 (49%) 42 (50%) 216 (49%) 0.81 
ACE-I, angiotensin converting enzyme inhibitor; ACh, acetylcholine; AF, 
atrial fibrillation; ARB, angiotensin receptor blocker; eGFR, estimated glomerular 
filtration rate; MINOCA, myocardial infarction with non-obstructive coronary 
arteries. 
 
 
Table 2. Adverse Events 
Variable All 
(n=529) 
Emergency 
(n=84) 
Non-Emergency 
(n=445) 
P value 
Major adverse events 7 (1.3%) 1 (1.2%) 6 (1.3%) 1.00 
Death 0 (0%) 0 (0%) 0 (0%) - 
VF or sustained VT 1 (0.2%) 0 (0%) 1 (0.2%) 1.00 
 Myocardial infarction 1 (0.2%) 0 (0%) 1 (0.2%) 1.00 
 Cardiogenic shock 3 (0.6%) 1 (1.2%) 2 (0.4%) 0.41 
Cardiac tamponade 0 (0%) 0 (0%) 0 (0%) - 
 Stroke 2 (0.4%) 0 (0%) 2 (0.4%) 1.00 
Non-major adverse events     
 Non-sustained VT 4 (0.8%) 1 (1.2%) 3 (0.7%) 0.50 
 AF 54 (10.2%) 11 (13.1%) 43 (9.7%) 0.33 
AF, atrial fibrillation; VF, ventricular fibrillation; VT, ventricular 
tachycardia.  
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